Trump again says he is considering reclassifying marijuana as less dangerous drug

President Trump said he is considering an executive order to reclassify marijuana from Schedule I to Schedule III, reiterating comments made earlier this year and on the campaign trail; a White House official cautioned that no final decision has been made. Rescheduling would not legalize or decriminalize cannabis but would ease research restrictions, make buying and selling simpler, potentially lower taxes and improve access to financing—moves that could materially benefit the multi‑billion-dollar cannabis industry and have previously driven stock gains. Critics including Sen. Ron Wyden note rescheduling would not expunge criminal records or fully legalize the drug, and prior reform efforts in the Biden administration and Congress have yet to be enacted.

Analysis

President Trump told reporters he is again weighing an executive order to reclassify marijuana from a Schedule I to a Schedule III controlled substance, reiterating comments made earlier this year and on the 2024 campaign trail; a White House official cautioned that no final decision has been made. The article notes Schedule I currently groups marijuana with heroin and ecstasy, while Schedule III includes substances such as Tylenol with codeine, ketamine and testosterone, illustrating the regulatory downgrade under consideration.

The piece highlights practical implications: reclassification would not legalize or decriminalize cannabis or expunge criminal records, but it would loosen research barriers and could make buying, selling, taxation and access to financing materially easier for the multi‑billion‑dollar cannabis industry. Earlier reports of potential easing of federal restrictions previously boosted cannabis stocks, underscoring a sensitivity of market pricing to regulatory signals.

Political and legislative risk remains significant: the Biden administration had explored reclassification without completing it, several congressional bills remain unpassed, and critics such as Sen. Ron Wyden warn rescheduling would not address criminal‑justice issues. The combined uncertainty around an executive action, congressional inaction and political pushback suggests a catalyst‑driven, binary risk profile for cannabis equities and related financings.

Key Decisions for Investors

• Consider modest, tactical exposure to U.S. cannabis equities or ETFs to capture upside from a potential reclassification-driven rerating, while keeping position sizes limited given high political and execution risk
• Monitor for concrete signals (White House confirmation, DOJ/DEA actions or formal executive order text) before adding material exposure, because the report states no final decision has been made
• Use hedges or maintain liquidity to protect against a reversal if rescheduling is delayed, blocked, or criticized, noting reclassification would not decriminalize or expunge records per the article
• Re-evaluate financing- and tax-sensitive names and private deal pipelines if a formal move occurs, since the article indicates reclassification could lower barriers to funding and reduce tax burdens for industry participants